Typical migraine as a complex disease: genetic epidemiology, twin and segregation analysis studies

That migraine runs in families is an ancient observation. Familiarity however is not synonymous with heritability, especially given the wide prevalence of migraine and the possibility that familial occurrence is due to chance. In order to assess the heritability of migraine, e.g. the rate of variance attributable to genetic factors, the disease risk of relatives of migraine probands is determined and compared to that found in the general population. Several surveys indicated that first- and sometimes also second-degree relatives of migraine probands show increased risk for migraine: a two-fold increased risk for migraine without aura (MO) and 1.4 for migraine with aura (MA) in the case of first-degree relatives of MO probands, and a 4-fold risk for MA in the case of first-degree relatives of MA probands [1]. An increased disease risk does not however prove heritability, since it may result from shared environmental factors. It is therefore interesting to note that at least one genetic epidemiology survey found an increased disease risk for migraine in first-degree relatives compared to spouses of migraine probands, who presumably share environmental factors at least for some time in their lives. Notably however, the relative risk for spouses was increased compared to the general population, which implies some degree of assorted mating or shared environmental influences [1]. Studies of heritability performed according to disease risk comparisons came to high rates of genetic determination, e.g. 60%–80% for MO and MA [2].

Better ways of analysing heritability of migraine are studies of monozygotic versus dizygotic twins, especially when reared-together and reared-apart (adopted) identical twins are considered. Several twin studies have been performed in migraine [3] (and tetrachoric correlations in female Danish twins [4]) and gave heritability estimates

Abstract Epidemiological genetic, family and twin studies show that the typical migraines carry a substantial genetic risk; they are currently conceptualized as complex genetic diseases. Several genetic association and linkage studies have been performed in the typical migraines. Candidate gene studies based on “a priori” pathogenic models of migraine (migraine as a calcium channelopathy; a mitochondrial DNA disorder; a disorder in the metabolism of serotonin or dopamine; in vascular risk factors or in the inflammation cascade; etc.) did not result in uniformly accepted findings. Linkage and genome wide scans gave evidence for several genetic susceptibility loci, still however in need of confirmation. Careful dissection of the clinical phenotypes and trigger factors shall greatly help future efforts in the quest for the genetic basis of the typical migraines.

Key words Migraine • Aura • Genetics • Cardiovascular risk
of about 50% for MO and MA, without important sex differences. They implied significant heritability rates for migraine with the remainder of variance being due to unshared environmental influences between twins [3]. It is likely however that such twins studies, performed in genetically and environmentally rather uniform populations, underestimate the role of environmental factors, or that at least they come close to the upper limit of heritability of the disease.

Even though they establish that migraine is heritable, these approaches cannot determine the pattern of heritability. Simple inspection of pedigrees was unable to determine the mode of hereditary transmission [5]. More recently, classic and complex segregation analysis of migraine pedigrees has shown that patterns of inheritance do not fit with simple mendelian rules of transmission, say an autosomal dominant with reduced penetrance or an autosomal recessive model, and that, even in families with an apparently autosomal dominant multigenerational pattern, a multifactorial inheritance is likely [6]. In some instances however, the influence of a single major gene or even hereditary patterns of sex-linked transmission or matrilineal heredity could not in principle be excluded [7]. Multifactorial inheritance implies that numerous genes, each having a small effect, segregate to produce the phenotype. In such a case, the result is a quantitative trait, e.g. a continuous varying character, to which each different gene or locus contributes in part (quantitative trait locus). There is, however, no evidence that migraine is a quantitative character, and indeed, it may be wrong to assume that complex human traits must all be the result of segregation at numerous interacting, rather than at a single or few major genetic liability loci; even complex animal behaviours have been shown to be regulated by a single major gene [8].

**The typical migraines: candidate-gene studies**

Candidate-gene studies are widely performed in the genetic analysis of complex traits, since the power of detecting genes involved in the etiopathogenesis of complex diseases is small with linkage studies. Association studies look at statistical correlation between some genetic variants and a phenotypic trait, and, if a candidate gene approach is chosen, a pathogenic hypothesis must first be generated in which genes involved in specific metabolic pathways or cellular functions are selected for analysis. This is understandably tricky however, and constitutes one of the difficulties with association studies, since an a priori assumption must be made, based on current fashionable but sometimes erroneous pathogenetic theories. Association studies also suffer from limitations common to epidemiological surveys, such as small sizes and selection bias in patient and control populations. As a result, these studies are often difficult to replicate. Moreover, genetic association is not proof of pathogenesis, and the involvement of the genetic variant must also be demonstrated on expression patterns and functional consequences. Pathogenetic theories of migraine abound, and many genes have consequently been subjected to association studies. These shall be examined according to the pathogenic model implicated.

**Migraine as a channelopathy**

The concept of migraine as a channelopathy was proposed by the Leiden school after the seminal genetic works on familial hemiplegic migraine (FHM) clarified FHM as a calcium channelopathy. The genetics of FHM are outside the scope of this review; they bear however on the genetics of the typical migraines, since FHM is considered a variety of migraine with aura, according to the IHS classification [9], and since it is clear, from detailed analysis of FHM pedigrees, that obligate carriers of the FHM mutation may display migraine with aura or without aura only, e.g. without hemiplegia. Several searches have therefore been made in order to assess the role of the FHM locus or the FHM mutations in the CACNA1A gene located on chromosome 19p13 in the genetics of the more common migraine types.

In 1995, May et al. tested the involvement of the 19p13 chromosomal region in 28 families with migraine with and without aura [10]. Sib-pair analysis showed that affected siblings shared the same highly informative marker allele (D19S394) more frequently than expected by chance, suggesting the involvement of 19p13 in the etiology of the common forms of migraine. Positive results were reported in 1998 also by Nyholt et al. [11] who studied one large family showing both cosegregation and significant allele sharing for markers situated across a 12.6-cM region containing the FHM Ca2+ channel gene. They concluded that mutations either in the CACNA1A gene or a closely linked gene were implicated in some pedigrees with familial typical migraine. As recently as 2001, Terwindt et al. [12] assessed the involvement of the 19p13 FHM locus in migraine with and without aura by analysing affected sib-pairs from 36 extended families with typical migraine with or without aura using flanking and CACNA1A intragenic markers. They found that sibling pairs with MA inherited the same 19p13 CACNA1A containing region significantly more frequently than expected by chance, consistently with an important involvement of this region in migraine, especially MA. Such results had led previously to the contention that the typical migraines could be conceptualized as calcium channelopathies, a concept useful also in
explaining their co-morbidity with ataxia and epilepsy, and applicable also to the animal models displaying mutations in the murine homologue of the human CACNA1A gene [13].

These positive studies, confirming the involvement of CACNA1A in the etiology of the more common forms of migraine, have been disputed. Thus, Hovatta et al. [14], studying typical migraines in a genetic isolate such as the Finnish population, did a linkage study on four families with multiple cases of migraine to markers on chromosome 19p. They excluded a region of 50 cM, flanking the FHM locus as a site of migraine liability. In our own study of 14 Italian families with MO and MA, we performed association, linkage and sib-pair analyses to markers near the CACNA1A region, with negative results [15]. In another study of Italian familial cases of “complicated” migraine, migraine stroke and MA [16], we reported the absence of the four original CACNA1A mutations described in FHM by Ophoff et al. [17]. Moreover, in their search for mutations in CACNA1A in nine families with migraine and episodic vertigo inherited in an autosomal dominant pattern, Kim et al. analysed all 47 exons and flanking introns of CACNA1A without finding any mutations, thus concluding that mutations in CACNA1A are not common in families with migraine headaches [18]. Even more recently, Jones et al. [19] analysed 16 families with MA for co-segregation with markers on 19p13, and obtained a lod score of 4.79 near D19S592, to a locus which however proved distinct from CACNA1A. Such a locus, distinct from CACNA1A and implicated in the genetics of MA, was later mapped, by the same group, to the insulin receptor gene, located on 19p13.3/2 [20]. It remains to be seen whether these latter results can explain the positive but controversial findings described previously. It appears therefore that, though not a liability for the typical migraines, mtDNA plays a role in the genetics of complicated migraine, especially migraine stroke, and of some migraine equivalents (Table 2).

| Table 1 mtDNA studies in migraine with negative results |
|---------------------------------------------------------|
| Klopstock et al. (1996) [25] 3243 MELAS, 8344 MERRF, mtDNA deletions absent in MA |
| Haan et al. (1999) [26] 3243 MELAS, 3271, 11084, mtDNA deletions absent in matrilinear migraines |
| Russell et al. (1997) [27] 11084 mutation absent in Danish migraineurs |
| Cortelli et al. 1995 [28] No tRNA Leu (UUR) mutation in cluster headache |
| Majamaa et al. (1998) [29] 8344, 8993, 11778, mtDNA deletions absent in migraine stroke |
| Buzzi et al. (2000) [30] 3243 MELAS mutation absent in multigenerational matrilinear migraine |

MA, migraine with aura
Migraine and serotonin metabolism genes

The rationale for exploring serotonin (5-HT) metabolism genes is based on the pathogenetic role assigned to serotonin in the migraine attack and on the documented efficacy of the several triptan drugs, which act at serotonin receptors 5-HT1B, D and F. Accordingly, serotonin metabolism genes have been considered promising candidate genes, but with scant success until now. All the studies performed on these receptors, including those with the aim of exploring whether the variable therapeutic response to triptans could be linked to genetic variations in these receptors, failed to detect any significant association or linkage (Table 3). Similar negative results were obtained for the 5-HT receptors 2A, 2B and 2C, the site of action of several prophylactic antimigraine drugs. The only study to report a significant association with migraine involved genetic variants of the 5-HT transporter SERT gene, in which an overrepresentation of allele Stin2.12 and a reduction of allele Stin2.10 were found in MO, with an additional trend to overrepresented Stin 2.9 allele in MA [39]. Exactly the opposite (increased Stin2.10 allele in migraine) was found by Yilmaz et al. [40], however, and negative findings were reported both by us in our sample of 14 Italian families with migraine [15] and by Lea et al. [41].

Migraine and dopamine metabolism genes

Here again the rationale depends on the features of dopaminergic hypersensitivity found in migraineurs and taken to explain symptoms such as yawning, nausea and vomiting, and hypotension during the attack, and on pharmacological evidence of increased dopamine receptors (DR) D2 and D4 on the surface of blood cells in migraineurs. However, the genetic evidence is murky, since positive studies of association with dopamine receptors genes, in particular DRD2, have been contradicted in other populations. NcoIC allele of the DRD2 gene was found associated with MA, and in particular with MA co-morbid with anxiety and depression, by

Table 2 mtDNA studies in migraine with positive results

| Study (Year) | mtDNA Mutations/Deletions |
|--------------|---------------------------|
| Bresolin et al. (1991) [23] | MtDNA deletion in 1 case with migraine stroke |
| Shimomura et al. (1995) [35] | 11084 mtDNA mutation in 25% of 53 Japanese migraineurs |
| Ojaimi et al. (1998) [32] | 4216 and 13708 LHON secondary mutations in juvenile stroke |
| Majamaa et al. (1997) [31] | MELAS mutation in 6% of juvenile migraine stroke |
| Majamaa et al. (1998) [29] | MtDNA U haplotype in migraine stroke |
| Finnila et al. (2001) [33] | MtDNA U5 haplotype and tRNA mutations in migraine stroke |
| Ohno et al. (1998) [36] | tRNA Glu and 12SrRNA mutations in matrilineal FHM |
| Shimomura et al. (1994) [37] | tRNA Leu UUR mutation in cluster headache |
| Odawara et al. (1997) [38] | MtDNA deletion in cluster headache |
| Boles et al. (1999) [34] | 8.1 kb mtDNA deletion in cyclic vomiting syndrome |

Table 3 Serotonin metabolism genes in migraine

| Gene (chromosome) | Allelic phenotype | Reference |
|-------------------|-------------------|-----------|
| 5-HTSERT (17q11.2-12) | Allelic association with MO (increased ST in 2.12 and decreased ST in 2.10 alleles) and MA (idem and increased Stin 2.9 alleles) | [39] |
| 5-HT2A (13q14-21) | Allelic association (C allele) with aura but not with migraine | [42] |
| 5-HT1B (6q13), 5-HT1D (1p36.3-34.3), 5-HT2B (2q36.3-q37.1), 5-HT2C (Xq22-25) | No association or linkage with migraine | [15, 43, 44] |
| 5-HT1B (6q13) | Not associated with therapeutic response to triptans | [46, 47] |
Peroutka et al. [48, 49], and Del Zompo et al. [50] found an association between DRD2 (but not DRD1 and DRD3) and MO in a sample of Sardinian families analysed by means of transmission dysequilibrium test: allele I of DRD2 was associated with yawning and nausea during the migraine attack, though not with migraine itself. Dichgans et al. [51], however, questioned these DRD2 findings: in their own population no particular association of Ncol allele with MA was found; moreover they pointed out that the allele is not functional, meaning that the particular DNA transition results in the same amino acid and protein and therefore does not change the function of the dopamine receptor. In addition, NcolC allele is the most frequent allele, and it is difficult to envisage that a disease is associated with the most frequent allele in the population. In our own study of dopamine metabolism genes [52], we performed an association study in MO and MA Italian patients with markers in the DRD2, DRD3 and COMT and MAO-A genes: all studies gave negative results. Again negative results with DRD2 markers were obtained by Lea et al. [41] and, more recently, Shepherd et al. [53] also reported negative association of migraine with DRD1, DRD3 and DRD5 genes. A positive association with a dopamine-beta-hydroxylase (DBH) intragenic dinucleotide polymorphism, with an altered allelic distribution between migraine and controls was found and confirmed by transmission dysequilibrium test implemented on the family data; DBH codes for an enzyme which catalyzes the transformation of dopamine into norepinephrine [41]. Like all of the previously mentioned studies on dopamine metabolism genes, this last finding has not been replicated yet, and the provisional conclusion must therefore be that no unequivocal role for dopamine metabolism genes has been ascertained in the typical migraines to date (Table 4).

Migraine and prothrombotic and vascular risk factor genes

Migraineurs carry a significant cardiovascular risk, and accordingly several investigators have explored genetic risk factors as candidate genes for migraine co-morbidity (Table 5). Overall, no significant association was found for genetic risk factors such as the Leiden factor V mutation (even though a single study reported positive findings), protein C and S deficiencies, factor II 20210 G/A mutation, factor XII Val34Leu polymorphism, the decanucleotide insertion/deletion in the factor VII promoter, and the platelet HPA-1 and HPA-2 alloantigentic systems. Likewise, association of migraine with the endothelial nitric oxide synthase (NOS3) and inducible nitric oxide synthase (iNOS) genes was negative, a rather dispiriting finding in view of the pathogenetic role attributed to nitric oxide metabolism in migraine [63, 64]. Positive findings were instead obtained with the angiotensin-converting enzyme gene deletion polymorphism, thought to be implicated in hypertension and cardiovascular risk, in which allele D was found significantly related to the frequency of the migraine attacks in 302 patients with MO [62], and with the endothelin type A receptor, in which allele G was shown to have a protective role against migraine [65]. This was a population based study, and the association was stronger in migraineurs with a family history of severe headaches. Finally, the homozygous C677T mutation in the methylenetetrahydrofolate reductase gene, which is responsible for hyperhomocysteinemia, was associated with migraine, especially MA [66]. These studies are intriguing but it must be remarked that not all of them have yet been replicated in independent populations.

Table 4 Dopamine metabolism genes and migraine

| Gene   | Phenotype                                      | Reference |
|--------|------------------------------------------------|-----------|
| DRD2   | Allelic association (Ncol allele) with MA      | [48]      |
| DRD1, DRD3, DRD4, DRD5 | No association with typical migraine | [41, 52, 53] |
| COMT, MAO-A | Allelic association with MA co-morbid with anxiety/depression | [49]      |
|        | Allelic association (Ncol allele) with MA co-morbid with anxiety/depression | [49]      |
|        | Allelic association (allele 1) with yawning/nausea during MO attack | [50]      |
|        | No allelic (Ncol allele) association with MA   | [51]      |
|        | No allelic association with MO/MA              | [52]      |
|        | No allelic association with migraine           | [41]      |
| DBH    | Allelic association with typical migraine      | [41]      |

MA, migraine with aura; MO, migraine without aura; DBH, dopamine beta-hydroxylase
Migraine and genes involved in inflammation

A few studies have addressed the problem of the role of genes coding for cytokines and other proteins involved in the inflammatory cascade. Peroutka et al. [54] studied polymorphism frequencies for complement C3F and C3S in a sample of 137 migraineurs and found that this common polymorphism had no association with migraine susceptibility. Trabace et al. [67] found that the frequency of TNFβ*2 allele, located in the HLA class III region, was significantly increased and that of TNFβ1 decreased in MO, suggesting that the TNFβ*2 allele confers a high risk for MO. The same group had previously observed a protective role for the HLA-DR2 antigen in MA [68]. Finally, a polymorphism in the interleukin-1alpha gene was found to influence age at onset of migraine and was associated with MA [69].

| Gene or mutation | Phenotype | Reference |
|-----------------|-----------|-----------|
| Factor V R/Q    | Associated with MA | [56] |
| (Leiden mutation) | No association with migraine stroke | [57] |
|                  | No association with MA/MO | [58] |
|                  | No association with juvenile MA | [59] |
| Factor II 20210 G/A | No association with MA or MO | [60] |
| Factor XIII Val34Leu polymorphism | No association with migraine | [61] |
| Decanucleotide insertion/deletion in the factor VII promoter | No association with MA or MO | [58] |
| Platelet HPA-1 and HPA-2 alloantigenic systems | No association with MA or MO | [58] |
| Protein S deficiency | Associated with MA | [56] |
| Angiotensin-converting enzyme (ACE) | D allele associated with MO and higher frequency of attacks | [62] |
| Endothelial/inducible nitric oxide synthase (NOS3; iNOS) | No linkage/association with migraine | [63, 64] |
| Endothelin type A receptor (ETA –231 A/G) polymorphism | G allele associated with protection from migraine | [65] |
| MTHFR (methylenetetrahydrofolate reductase) C677T mutation | Homozygous mutation associated with migraine, especially MA | [66] |

MA, migraine with aura; MO, migraine without aura

Genetics of the typical migraines: other linkage studies

Other genetic studies have investigated some chromosomal regions chosen either for their involvement in FHM or for considerations derived from the genetic epidemiology of the disease. Thus, considering the increased prevalence of migraine among females and in first-degree relatives of male probands affected with migraine, Nyholt et al. [70] performed linkage studies looking for an X-linked component in migraine. Of three large multigenerational migraine pedigrees, two showed significant excess allele sharing to Xq markers. In a later more detailed study, they were able to establish significant linkage to Xq24-28 [71] in two large Australian pedigrees, thus providing compelling evidence for a migraine susceptibility locus on chromosome Xq24-28. Taking into consideration the recently reported linkage of FHM to chromosome 1, Lea et al. [55]
explored the possibility that such chromosomal region was also implicated in typical migraines. In a migraine Australian pedigree, they found strong evidence for linkage to chromosome 1q31 markers, with the interval for suggestive linkage spanning approximately 18 cM and a maximum allele sharing LOD score of 3.36 for marker D1S2782. Linkage was validated in an independent sample of 82 affected pedigrees, giving evidence for a typical migraine locus near chromosome 1q31 and suggesting that the second locus for FHM may contribute to susceptibility to the more common forms of migraine. In regard instead to the first FHM locus at 19p13, we saw before how Jones et al. [19] were able to identify a susceptibility locus for the typical migraines at 19p13 but distinct from CACNA1A. In a later refinement of this work, McCarthy et al. [20] investigated this migraine locus by means of linkage and association analysis with 48 single-nucleotide polymorphisms (SNIPs) within the locus in a population of 827 migraineurs and 765 controls. Five SNIPs within the insulin receptor gene INSR showed significant association with migraine, and the association was independently replicated in a separate case-control population. This association of migraine with the INSR could explain the epidemiological association between migraine and diabetes mellitus/hypertension, and why fasting is a migraine trigger factor. However, the role of INSR remained unclear, since the study showed that INSR mRNA levels (in blood) were no different between phenotypes, and that there were no aberrant transcripts, implying normal expression of the gene; moreover binding of 125I-insulin (in mononuclear cells) was also unaffected, and there were no differences in clinical parameters among controls and migraineurs. These caveats notwithstanding, the INSR represents an intriguing associated gene since it is present in brain cells and may regulate energy metabolism; however, if not functional, it could still be in linkage disequilibrium with a yet unidentified gene.

**Genetics of the typical migraines: genome-wide scans**

Genome-wide scans are performed to dissect multilocus inheritance into quantitative trait loci (QTLs) and to map them to specific chromosomal regions. They rely on markers that are evenly spaced throughout the genome, and, in contrast to the candidate genes approach, have no regard to their function or the context within a specific gene (they need no a priori hypothesis). This makes genome-wide scans particularly useful in complex diseases. A kind of genome-wide scan, though rather simple in conception, was the work of Pardo et al. [72], who utilized eleven genetic blood markers typed in 112 migraineurs and compared with a random sample of healthy individuals. Strong associations were found between migraine and group-specific component GC 1F-1F and esterase-D ESD 2–2, located on chromosomes 4 and 13, respectively. Wessman et al. [73] performed a genome-wide screen of 50 multigenerational Finnish families with MA, using 350 polymorphic microsatellite markers with an average intermarker distance of 11 cM. They found significant linkage with D4S1647 on 4q24 and no other chromosomal region.

**Genetics of the typical migraines: conclusive considerations**

Even this short exposition of the principal genetic investigations performed in the typical migraines demonstrates the bewildering array of results obtained, and how most of them are plagued by a frequent problem in the studies of complex diseases, i.e. non-replication. Other results still await confirmation in independent population samples. Therefore it is safe to assume that there is still no confirmed genetic liability locus for the “typical” migraine headaches. Non-replication is so frequently encountered in the genetic studies of complex diseases that widespread scepticism surrounds association studies especially when performed with the candidate-gene approach. Are we therefore dealing with faulty methodology?

Several problems concur in non-replication: definition of phenotype may vary across different populations and different studies; most studies have been performed on small numbers, without consideration of the power necessary for significant results and without considering that migraine is very prevalent and carries a relatively small magnitude of relative risk (association studies give difficult results when the relative risk is less than 10); moreover, no study has taken into consideration of environmental factors modifying the relationship between genotype and disease; some studies selected polymorphisms either too rare (<5%) in the general population, or that were not functional, leading to over-reliance on linkage disequilibrium; many studies do not entertain the expression of the genes investigated. To these methodological shortcomings must be added the lack of some rigorous epidemiological principles: use of inappropriate control groups, patient cohorts selected from tertiary care centers and not from the general population, etc. To all of these methodological problems we could add some erroneous assumptions that we make in the genetics of migraine. The assumption that migraine results from the interaction of tens or even hundreds of genes each carrying a small genetic load and interacting, intercalated in metabolic pathways so diverse and ranging from ion channels to inflammatory proteins and mitochondrial DNA does not make much clinical sense. Such a view of migraine as a genetic “fruit salad” is moreover rather dispiriting: since each gene carries a small genetic risk, it does not represent a worthwhile target for therapeutic modifications, which would only marginally
affect the phenotypic expression of the disease. Migraine is, however, internally consistent in its phenotypic expression through age, sex, census and populations, and deserves consideration as a disease with intrinsic pathogenic autonomy. We must remember that even complex diseases may stem from the effects of a few major single genes. Probably, a more careful distillation of the phenotypic expression of migraine and of its trigger factors, e.g. more clinical ingenuity and judgement, shall serve the quest for the genetic basis of the typical migraines better.

The typical migraines: a time for pharmacogenetics?

Much hype has been afforded by the possible developments in pharmacogenetics. In the case of the typical migraines, where we have still no definite genes in our hands, the time for pharmacogenetics has yet to come. Still, it is possible to make conjectures and to envisage possible avenues for pharmacological research. Knowledge of the genetics of FHM makes the P/Q calcium channels possible targets for new drugs even for the typical migraines; moreover, we can expect useful information from studies of channel characteristics in mouse mutants and in channels expressed in oocytes or in cultivated cells. Pharmacogenetics could also take advantage of gene polymorphisms to tailor pharmacological treatment, and in this regard several examples are possible, for instance taking note of polymorphisms in the 5-HT1B receptor gene (the Cys124 polymorphism) and in the 5-HT2C gene (the Cys23-Ser23) which are already known to affect negatively the binding of dyhydroergotamine, sumatriptan and serotonin [74, 75]. Finally, we could discern and take into consideration the role of modifying genes (e.g. 5-HT and dopamine metabolism genes, prothrombotic/vascular risk factors) in the treatment of migraine attacks and migraine co-morbidity. All of this is for the future. At the moment, the only two works that studied the therapeutic response to sumatriptan in migraineurs found no association with genetic variation at the 5-HT receptor 1B and 1F genes [46, 47].

Post-scriptum Recently, other susceptibility loci for migraine have been identified on 6p12.2-p21.1 (Carlsson et al. Neurology 2002;59:1804–7) and 14q21.2-q22.3 (Soragna et al. Am J Hum Genet 2003;72:161–7), and the gene (ATP1A2) for FHM2 has been identified (De Fusco et al. Nat Genet 2003;33:192–6).

Acknowledgements Thanks are due to Ms. A. Collins for reviewing the English text and Ms. A. Laffi for editing the manuscript. This work was supported by CNR grant no. 99.02536.CT04 and MURST ex-60% 1999-2000-2001 grant.

References

1. Russell MB, Olesen J (1995) Increased familial risk and evidence of a genetic factor in migraine. BMJ 31:541–544
2. Mochi M, Sangiorgi S, Cortelli P, Carelli V, Scapoli C, Crisci M, Monari L, Pierangeli G, Montagna P (1993) Testing models for genetic determination in migraine. Cephalalgia 13:389–394
3. Ziegler DK, Hur YM, Bouchard TJ Jr, Hassanein RS, Barter R (1998) Migraine in twins raised together and apart. Headache 38:417–422
4. Gervil M, Ulrich V, Kylvik KO, Olesen J, Russell MB (1999) Migraine without aura: a population-based twin study. Ann Neurol 46:606–611
5. Devoto M, Lozito A, Staffa G, D’Alessandro R, Sacquegna T, Romeo G (1986) Segregation analysis of migraine in 128 families. Cephalalgia 6:101–105
6. Russell MB, Iselius L, Olesen J (1995) Investigation of inheritance of migraine by complex segregation analysis. Hum Genet 96:726–730
7. Kalfakis N, Panas M, Vassilopoulos D, Malliara-Loulakaki S (1996) Migraine with aura: segregation analysis and heritability estimation. Headache 36:320–322
8. Krieger MJ, Ross KG (2002) Identification of a major gene regulating complex social behavior. Science 295:328–332
9. – (1988) Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society. Cephalalgia 8(Suppl 7):1–97
10. May A, Ophoff RA, Terwindt GM, Urban C, van Eijk J, Diener HC, Lindhout D, Frants RR, Sandkuijl LA et al (1995) Familial hemiplegic migraine locus on 19p13 is involved in the common forms of migraine with and without aura. Hum Genet 96(5):604–608
11. Nyholt DR, Lea RA, Gwashby PJ, Brimage PJ, Griffiths LR (1998) Familial typical migraine: linkage to chromosome 19p13 and evidence for genetic heterogeneity. Neurology 50(5):1428–1432
12. Terwindt GM, Ophoff RA, van Eijk J, Vergouwe MN, Haan J, Frants RR, Sandkuijl LA, Ferrari MD (2001) Involvement of the CACNA1A gene containing region on 19p13 in migraine with and without aura. Neurology 56(8):1028–1032
13. Terwindt GM, Ophoff RA, Haan J, Sandkuijl LA, Frants RR, Ferrari MD (1998) Migraine, ataxia and epilepsy: a challenging spectrum of genetically determined calcium channelopathies. Dutch Migraine Genetics Research Group. Eur J Hum Genet 6:297–307
14. Hovatta I, Kallela M, Farkkila M, Peltonen L (1994) Familial migraine: exclusion of the susceptibility gene from the reported locus of familial hemiplegic migraine on 19p. Genomics 23(3):707–709
15. Monari L, Mochi M, Valentino ML, Arnaldi C, Cortelli P, De Monte A, Pierangeli G, Prologo G, Scapoli C, Soriani S, Montagna P (1997) Searching for migraine genes: exclusion of 290 cM out of the whole human genome. Ital J Neurol Sci 8(5):277–282
16. Cevoli S, Valentino ML, Mochi M, Carelli V, Soriani S, Morandi C, Pulimenno P, Granella F, Cortelli P, Montagna P (1997) Molecular analysis on migraine patients: exclusion of mutations in CACNL1A4 Gene. Ital J Neurol Sci 4[Suppl]:59 (abstract)

17. Ophoff RA, Terwindt GM, Vergouwe MN, van Eijk J, Oefner PJ, Hoffman SM, Lamerdin IE, Mohrenweiser HW, Bulman DE, Ferrari M, Haan J, Lindhout D, van Ommen GJ, Hofker MH, Ferrari MD, Frants RR (1996) Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 87:543–552

18. Kim JS, Yue Q, Jen JC, Nelson SF, Baloh RW (1998) Familial migraine with vertigo: no mutations found in CACNA1A. Am J Med Genet 79(2):148–151

19. Jones KW, Ehm MG, Pericak-Vance MA, Haines JL, Boyd PR, Peroutka SJ (2001) Migraine with aura susceptibility locus on chromosome 19p13 is distinct from the familial hemiplegic migraine locus. Genomics 78:150–154

20. McCarthy LC, Hosford DA, Riley JH, Bird MI, White NJ, Hewett DR, Peroutka SJ, Griffiths LR, Boyd PR, Lea RA, Bhatti SM, Hosking LK, Hood CM, Jones KW, Handley AR, Rallan R, Lewis KF, Yeo AJ, Williams FM, Priest RC, Khan P, Donnelly C, Lumsden SM, O’ Sullivan J, See CG, Smart DH, Shaw-Hawkins S, Patel J, Langrish TC, Feniuk W, Knowles RG, Thomas M, Libri V, Montgomery DS, Manasco PK, Xu CF, Dykes C, Humphrey PP, Roses AD, Purvis JI (2001) Single-nucleotide polymorphism alleles in the insulin receptor gene are associated with typical migraine. Genomics 78:135–149

21. Montagna P, Gallassi R, Medori R, Govoni E, Zeviani M, Di Mauro S, Lugaresi E, Andermann F (1988) MELAS syndrome: characteristics, migrainous epiletic features and maternal transmission. Neurology 38:751–754

22. Schoenen J, Jacquot J, Lenaerts M (1998) Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology 50:466–470

23. Bresolin N, Martinelli P, Barbini B, Zanoli P, Aussenda C, Montagna P, Gallant A, Comi GP, Scarlato G, Lugaresi E (1991) Muscle mitochondrial DNA deletion and 31P-NMR spectroscopy alterations in a migraine patient. J Neurol Sci 104:182–189

24. Montagna P, Sacquegna T, Cortelli P, Lugaresi E (1999) Migraine as a defect of brain oxidative metabolism: a hypothesis. J Neurol 236:123–125

25. Klopstock T, May A, Seibel P, Papagianuli E, Diener HC, Reichmann H (1996) Mitochondrial DNA in migraine with aura. Neurology 46:1735–1738

26. Haan J, Terwindt GM, Maassen JA, Hart LM, Frants RR, Ferrari MD (1999) Search for mitochondrial DNA mutations in migraine subgroups. Cephalalgia 19:20–22

27. Russell MB, Diamant M, Norby S (1997) Genetic heterogeneity of migraine with and without aura in Danes cannot be explained by mutation in mtDNA nucleotide pair 11084. Acta Neurol Scand 96:171–173

28. Cortelli P, Zacchini A, Barboni P, Malpassi P, Carelli V, Montagna P (1995) Lack of association between mitochondrial tRNA^{Aur(UUR)} point mutation and cluster headache. Lancet 345:1120–1121

29. Majamaa K, Finnila S, Turkka J, Majamaa K, Kinnula V, Turkka J, Hassinen IE (1998) Mitochondrial DNA haplogroup U as a risk factor for occipital stroke in migraine. Lancet 352:455–456

30. Buzzi MG, Di Gennaro G, D’Onofrio M, Ciccarelli O, Santorelli FM, Fortini D, Nappi G, Nicoletti F, Casali C (2000) mtDNA A3243G MELAS mutation is not associated with multigenerational female migraine. Neurology 54:1005–1007

31. Majamaa K, Turkka J, Karppa M, Winquist S, Hassinen IE (1997) The common MELAS mutation A3243G in mitochondrial DNA among young patients with an occipital brain infarct. Neurology 49:1331–1334

32. Ojaimi J, Katsabanis S, Bower S, Olesen J (1997) Lack of association between mitochondrial DNA deletions. Muscle Nerve 20:394–395

33. Ogilvie AD, Russell MB, Dhall P, Battersby S, Ulrich V, Smith CA, Goodwin GM, Harmar AJ, Olesen J (1998) Altered allelic distribution of the serotonin transporter gene in migraine without aura and migraine with aura. Cephalalgia 18:23–26

34. Yilmaz M, Erdal ME, Herken H, Cataloluk O, Barlas O, Bayazit YA (2001) Significance of serotonin transporter gene polymorphism in migraine. J Neurol Sci 186:27–30

35. Shimomura T, Kitano A, Marukawa H, Takahashi K (1995) Mutation in platelet mitochondrial gene in patients with migraine. Cephalalgia 15(13):10

36. Ohno K, Tanaka M, Takano A, Teramoto J (1998) Point mutations of mitochondrial DNA in familial hemiplegic migraine. JAMA 279:1170–1171

37. Shimomura T, Kitano A, Marukawa H, Mishima K, Isoe K, Adachi Y, Takahashi K (1994) Point mutation in platelet mitochondrial tRNA (Leu(UUR)) in patients with cluster headache. Lancet 344:625 (letter)

38. Oda M, Tomaka M, Mizusawa H, Yamashita K (1997) A case of cluster headache associated with mitochondrial DNA deletions. Muscle Nerve 20:394–395

39. Ogilvie AD, Russell MB, Dhall P, Battersby S, Ulrich V, Smith CA, Goodwin GM, Harmar AJ, Olesen J (1998) Altered allelic distribution of the dopamine beta-hydroxylase gene (DBH) with susceptibility to typical migraine. Neurogenetics 3:35–40

40. Erdal ME, Herken H, Yilmaz M, Bayazit YA (2001) Association of the T102C polymorphism of 5-HT2A receptor gene with aura in migraine. J Neurol Sci 188:99–101

41. Nyholt DR, Curtin RP, Gaffney PT, Brimage PJ, Griffiths LR (2000) Evidence for allelic association of the dopamine beta-hydroxylase gene (DBH) with susceptibility to typical migraine. Neurogenetics 3:35–40

42. Erkal ME, Herken H, Yilmaz M, Bayazit YA (2001) Association of the T102C polymorphism of 5-HT2A receptor gene with aura in migraine. J Neurol Sci 188:99–101

43. Nyholt DR, Curtin RP, Gaffney PT, Brimage PJ, Griffiths LR (1996) Migraine association and linkage analyses of the human 5-hydroxytryptamine (5HT_2A) receptor gene. Cephalalgia 16:463–467

44. Buchwalder A, Welsh SK, Peroutka SJ (1996) Exclusion of 5-HT2A and 5-HT2C receptor genes as candidate genes for migraine. Headache 36:254–258

45. Burnet PW, Harrison PJ, Goodwin GM, Battersby S, Ogilvie AD, Olesen J, Russell MB (1997) Allelic variation in the serotonin 5-HT2C receptor gene and migraine. Neuroreport 8:2651–2653
56. Maassen Van Den Brink A, Vergouwe MN, Ophoff RA, Saxena PR, Ferrari MD, Frants RR (1998) 5-HT1B receptor polymorphism and clinical response to sumatriptan. Headache 38:288–291
57. Maassen Van Den Brink A, Vergouwe MN, Ophoff RA, Naylor SL, Dauweuser HG, Saxena PR, Ferrari MD, Frants RR (1998) Chromosomal localization of the 5-HT1F receptor gene: no evidence for involvement in response to sumatriptan in migraine patients. Am J Med Genet 77:415–420
58. Peroutka SJ, Wilhoit T, Jones K (1997) Clinical susceptibility to migraine with aura is modified by dopamine D2 receptor (DRD2) NcoI alleles. Neurology 49:201–206
59. Peroutka SJ, Price SC, Wilhoit TL, Jones KW (1998) Comorbid migraine with aura, anxiety, and depression is associated with dopamine D2 receptor (DRD2) NcoI alleles. Mol Med 4:14–21
60. Del Zompo M, Cherchi A, Palmas MA, Ponti M, Boccetta A, Gessa GL, Piccardi MP (1998) Association between dopamine receptor genes and migraine without aura in a Sardinian sample. Neurology 51:781–786
61. Dichgans M, Förderreuther S, Deiterich M, Pfaffenrath V, Gasser T (1998) The D2 receptor NcoI allele: Absence of allelic association with migraine with aura. Neurology 51:928 (abstract)
62. Mochi M, Monari L, Valentino ML, Cevoli S, Cortelli P, Pierangeli G, Soriani S, Montagna P (2000) Migraine and dopamine metabolism related genes: a genetic association study. Cephalalgia 20:265–267
63. Shepherd AG, Lea RA, Hutchins C, Jordan KL, Brimage PJ, Griffiths LR (2002) Dopamine receptor gene polymorphisms and migraine with and without aura: a association study. Headache 42:346–351
64. Peroutka SJ, Price SC, Jones KW (1997) The comorbid association of migraine with osteoarthritis and hypertension: complement C3F and Borkson’s bias. Cephalalgia 17(1):23–26
65. Lea RA, Shepherd AG, Curtain RP, Nyholt DR, Quinlan S, Brimage PJ, Griffiths LR (2002) A typical migraine susceptibility region localizes to chromosome 1q31. Neurogenetics 4:17–22
66. D’Amico D, Moschiano F, Leone M, Ariano C, Ciusani E, Erba N, Grazzi L, Ferrarisi A, Schieroni F, Mussone G (1998) Genetic abnormalities of the protein C system: shared risk factors in young adults with migraine with aura and with ischemic stroke? Cephalalgia 18:618–621
67. Haan J, Terwindt GM, Ferrari MD (1997) Genetics of migraine. Neurol Clin 15:43–60
68. Corral J, Iniesta JA, Gonzalez-Conejero R, Lozano ML, Rivera J, Vicente V (1998) Migraine and prothrombotic genetic risk factors. Cephalalgia 18:257–260
69. Sortani S, Borgia-Pignatti C, Trabetti E, Casartelli A, Montagna P, Pignatti PF (1998) Frequency of factor V Leiden in juvenile migraine with aura. Headache 38:779–781
70. Haan J, Kappelle LJ, Ferrari MD, Bertina RM (1998) The transition G to A at position 20210 in the 3' untranslated region of the prothrombin gene is not associated with migrainous infarction. Cephalalgia 18:229–230
71. Iniesta JA, Corral J, Gonzalez-Conejero R, Diaz Ornuto A, Martinez Navarro ML, Vicente V (2001) Role of factor XIII Val 34 Leu polymorphism in patients with migraine. Cephalalgia 21:837–841
72. Paterna S, Di Pasquale P, D’Angelo A, Seidita G, Tuttolomendo A, Cardinale G, Maniscalchi T, Follone G, Giubilato A, Tarantello M, Licata G (2000) Angiotensin-converting enzyme gene deletion polymorphism determines an increase in frequency of migraine attacks in patients suffering from migraine without aura. Eur Neurol 43:133–136
73. Griffiths LR, Nyholt DR, Curtain RP, Brimage PJ, Goodyer PJ, Nicholson GA, Griffiths LR (1998) Evidence for an X-linked component in familial typical migraine. Hum Mol Genet 7:459–463
74. Nyholt DR, Curtain RP, Griffiths LR (2000) Familial typical migraine: significant linkage and localization of a gene to Xq24–28. Hum Genet 107:18–23
75. Pardo J, Carracedo A, Munoz I, Castillo J, Lema M, Noya M (1995) Genetic markers: association study in migraine. Cephalalgia 15:200–204
76. Wessman M, Kallela M, Kaunisto MA, Marttila P, Solberg E, Hartiala J, Owosekun K, Leal SM, Papp JC, Hamalainen E, Hartiala J, Oswell RM, Zwart JA, Ilmavirta M, Havanka F, Farkkila M, Petlonen L, Polatie A (2002) A susceptibility locus for migraine with aura, on chromosome 4q24. Am J Hum Genet 70:652–662
77. Lappalainen J, Zhang L, Dean M, Oz M, Ozaki N, Yu D-H, Virkunen M, Weight F, Linnoila M, and Goldman D (1995) Identification, expression, and pharmacology of a Cys23-Ser23 substitution in the human 5-HT2C receptor gene (HTR2C). Genomics 27:274–279
78. Brüss M, Bönisch H, Bühlen M, Nöthen MM, Propping P, Göttel M (1999) Modified ligand binding to the naturally occurring Cys-124 variant of the human serotonin 5-HT1B receptor. Pharmacogenetics 9:95–102